Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma.

Lea GrümmeEva BiewaldMadlen ReschkeKaren FischhuberAnna HanbückenSabrina SchlüterBert MüllerTobias KieferSophia GörickeDirk GeismarTatsiana RylSelma SirinRegina WielandBeate TimmermannDietmar LohmannMartin EbingerInes B BrechtStefan SchönbergerChristoph SchwabAngelika EggertDaniela SüsskindPetra Ritter-SovinzNikolaos E BechrakisPetra Ketteler

Published in: Pediatric blood & cancer (2021)

Despite omitting cyclophosphamide, the EFES was higher after VEC chemotherapy that contains higher doses of carboplatin compared to CyVEC. The major risk factor for enucleation was advanced ICRB tumor grouping. Randomized clinical trials on efficacy and side effects of eye-preserving chemotherapy are required to tailor treatment protocols for retinoblastoma patients.

Keyphrases

locally advanced
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
young adults
peritoneal dialysis
prognostic factors
low dose
squamous cell carcinoma
phase ii study
clinical trial
chemotherapy induced
high dose
mesenchymal stem cells
bone marrow
rectal cancer
study protocol